Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug-Resistant Epilepsy Clear all
Terminated Not applicable Interventional

Exercise as Adjunctive Treatment for Refractory Epilepsy

NCT04607317
View directory record Official record
Conditions
Refractory Epilepsy, Epilepsy
Interventions
Exercise program, Health Coach, Health Information
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

NCT00228969
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
RWJ-333369
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707
View directory record Official record
Conditions
Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure, Seizure Disorder
Interventions
NaviFUS System
Device
Lead sponsor
NaviFUS Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Neural Mechanisms of Spatial Representations Beyond the Self

NCT05406349
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Self-navigation task, Observation task
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial

NCT03868293
View directory record Official record
Conditions
Drug Resistant Epilepsy
Interventions
Focused ultrasound
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy

NCT02426047
View directory record Official record
Conditions
Epilepsy, Seizure, Catamenial Epilepsy, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions
betaquik®
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 22, 2026, 4:57 AM EDT
Not listed Phase 4 Interventional

Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy

NCT01932502
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
clobazam (Onfi), Initial conversion and titration, Conversion schedule - Week 1, Conversion schedule - Week 2, Conversion schedule - Week 3
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

NCT02758626
View directory record Official record
Conditions
Epilepsy
Interventions
ataluren, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 12 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 22, 2026, 4:57 AM EDT
Not yet recruiting Not applicable Interventional

Overnight TI in TLE

NCT07434986
View directory record Official record
Conditions
Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy, Sleep
Interventions
Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Enrolling by invitation No phase listed Observational

5-SENSE Score Validation Study

NCT06138808
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Stereoelectroencephalography (SEEG)
Other
Lead sponsor
Duke University
Other
Eligibility
15 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 22, 2026, 4:57 AM EDT
Enrolling by invitation Not applicable Interventional

Neural Computations of Goal-directed Decision-making

NCT06489561
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

External Trigeminal Nerve Stimulation for Epilepsy

NCT01159431
View directory record Official record
Conditions
Epilepsy, Seizure Disorders
Interventions
Trigeminal Nerve Stimulation
Device
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 3 Interventional Results available

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Phase 2 Interventional

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

NCT05518578
View directory record Official record
Conditions
Epilepsy, Seizures, Epileptic
Interventions
SPN-817
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Not listed Not applicable Interventional

Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy

NCT03857074
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable
Interventions
Green Light Exposure
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

NCT06425159
View directory record Official record
Conditions
Generalized Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134
View directory record Official record
Conditions
Epilepsy
Interventions
Carvedilol-CR
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 22, 2026, 4:57 AM EDT